Clinical results of an automated artificial pancreas using technosphere inhaled insulin to mimic first-phase insulin secretion

Journal of Diabetes Science and Technology

Volumn 9, Issue 3, 2015, Pages 564-572

  Zisser, Howard ^a   Dassau, Eyal ^a,b   Lee, Justin J ^a   Harvey, Rebecca A ^a   Bevier, Wendy ^a   Doyle, Francis J ^a,b  

^a University of California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Artificial pancreas; Closed loop; Glucose control; Health Monitoring System; Hypoglycemia mitigation; inhaled insulin; telemedicine; type 1 diabetes; Unannounced meals; Zone MPC

Indexed keywords

GLUCOSE; INSULIN; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO; SHORT ACTING INSULIN; TECHNOSPHERE INSULIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ALGORITHM; ARTICLE; ARTIFICIAL PANCREAS; BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DELIVERY DEVICE; EXERCISE; FEMALE; FOLLOW UP; GLUCOSE SENSOR; HEART RATE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INSULIN RELEASE; MALE; MEAL; MIDDLE AGED; MODEL; POSTPRANDIAL STATE; TIME; BIOASSAY; BLOOD; DIABETES MELLITUS, TYPE 1; EATING; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; METABOLISM; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; EATING; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; PANCREAS, ARTIFICIAL;

EID: 84939433124     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296815582061     Document Type: Article

References (50)

1. Abbes IB, Richard PY, Lefebvre MA, Guilhem I, Poirier JY. A closed-loop artificial pancreas using a proportional integral derivative with double phase lead controller based on a new nonlinear model of glucose metabolism. J Diabetes Sci Technol. 2013;7(3):699-707.
2. Turksoy K, Bayrak ES, Quinn L, Littlejohn E, Cinar A. Multivariable adaptive closed-loop control of an artificial pancreas without meal and activity announcement. Diabetes Technol Ther. 2013;15(5):386-400.
3. Yaturu S. Insulin therapies: current and future trends at dawn. World J Diabetes. 2013;4(1):1-7.
4. Tsukamoto Y, Kinoshita Y, Kitagawa H, et al. Evaluation of a novel artificial pancreas: closed loop glycemic control system with continuous blood glucose monitoring. Artif Organs. 2013;37(4):E67-E73.
5. Nimri R, Danne T, Kordonouri O, et al. The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial. Pediatr Diabetes. 2013;14(3):159-167.
6. Thabit H, Hovorka R. Closed-loop insulin delivery in type 1 diabetes. Endocrinol Metab Clin North Am. 2012;41(1):105-117.
7. Haidar A, Legault L, Dallaire M, et al. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ. 2013;185(4):297-305.
8. Bayrak ES, Turksoy K, Cinar A, Quinn L, Littlejohn E, Rollins D. Hypoglycemia early alarm systems based on recursive autoregressive partial least squares models. J Diabetes Sci Technol. 2013;7(1):206-214.
9. van Heusden K, Dassau E, Zisser HC, Seborg DE, Doyle FJ III. Control-relevant models for glucose control using a priori patient characteristics. IEEE Trans Biomed Eng. 2012;59(7):1839-1849.
10. Valla V. Continuous subcutaneous insulin infusion (CSII) pumps. Adv Exp Med Biol. 2012;771:414-419.
11. Kowalski AJ. Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a road-map to better diabetes outcomes. Diabetes Technol Ther. 2009;11:S113-S119.
12. Stenvers DJ, Devries JH, la Fleur SE. What's the time? Does the artificial pancreas need to know? Diabetes. 2013;62(7): 2173-2174.
13. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes. 2006;55(12):3344-3350.
14. Dassau E, Zisser H, Harvey RA, et al. Clinical evaluation of a fully automated personalized artificial pancreas with an unannounced meal using mpMPC and insulin-on-board. Diabetes Care. 2013;36:801-809.
15. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008;31(5):934-939.
16. Ricotti L, Assaf T, Dario P, Menciassi A. Wearable and implantable pancreas substitutes. J Artif Organs. 2013;16(1): 9-22.
17. Russell SJ, El-Khatib FH, Nathan DM, Magyar KL, Jiang J, Damiano ER. Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care. 2012;35(11):2148-2155.
18. Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet. 2010;375(9716):743-751.
19. Breton M, Farret A, Bruttomesso D, et al. Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes. 2012;61(9):2230-2237.
20. Steil GM, Palerm CC, Kurtz N, et al. The effect of insulin feedback on closed loop glucose control. J Clin Endocrinol Metab. 2011;96(5):1402-1408.
21. Castle JR, Engle JM, Youssef JE, et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care. 2010;33(6):1282-1287.
22. Lee JJ, Dassau E, Zisser H, Harvey RA, Jovanovic L, Doyle FJ III. In silico evaluation of an artificial pancreas combining exogenous ultrafast-acting technosphere insulin with zone model predictive control. J Diabetes Sci Technol. 2013;7(1):215-226.
23. Polonsky KS, Given BD, Hirsch L, et al. Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest. 1988;81(2):435-441.
24. Brange J. Chemical stability of insulin. 4. Mechanisms and kinetics of chemical transformations in pharmaceutical formulation. Acta Pharm Nord. 1992;4(4):209-222.
25. Harvey RA, Dassau E, Zisser HC, et al. Clinically relevant hypoglycemia prediction metrics for event mitigation. Diabetes Technol Ther. 2012;14(8):719-727.
26. Teutsch SM, Herman WH, Dwyer DM, Lane JM. Mortality among diabetic patients using continuous subcutaneous insulin-infusion pumps. New Engl J Med. 1984;310(6):361-368.
27. Siperstein MD. Diabetic ketoacidosis and hyperosmolar coma. Endocrinol Metab Clin North Am. 1992;21(2):415-432.
28. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med. 2013;368(9):824-833.
29. Dassau E, Hennings T, Fazio J, Atlas E, Phillip M. Closing the loop. Diabetes Technol Ther. 2013;15(suppl 1):S29-S39.
30. Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clin Ther. 2009;31(5):980-987.
31. Renard E, Place J, Cantwell M, Chevassus H, Palerm CC. Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery. Diabetes Care. 2010;33(1):121-127.
32. DeFelippis MR, Chance RE, Frank BH. Insulin self-association and the relationship to pharmacokinetics and pharmacody-namics. Crit Rev Ther Drug Carrier Syst. 2001;18(2):201-264.
33. Gaensslen M. Uber inhalation von Insulin. Klin Wochenschr. 1925;2:71-72.
34. Rave K, Potocka E, Boss AH, Marino M, Costello D, Chen R. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab. 2009;11(7):715-720.
35. Wang X, Rajaraman S, DeHennis A. Real-time lag compensation for a subcutaneously implanted fluorescent glucose sensor. Paper presented at: 6th Conference on Advanced Technologies & Treatments for Diabetes, 2013; Paris, France.
36. Saudek CD, Selam JL, Pitt HA, et al. A preliminary trial of the programmable implantable medication system for insulin delivery. N Engl J Med. 1989;321(9):574-579.
37. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471.
38. Renard E. Implantable insulin delivery pumps. Minim Invasive Ther Allied Technol. 2004;13:328-335.
39. Colvin AE, Jiang H. Increased in vivo stability and functional lifetime of an implantable glucose sensor through platinum catalysis. J Biomed Mater Res A. 2013;101:1274-1282.
40. Broussolle C, Jeandidier N, Hanaire-Broutin H. French multicentre experience of implantable insulin pumps. The EVADIAC Study Group. Evaluation of Active Implants in Diabetes Society. Lancet. 1994;343(8896):514-515.
41. Benefit/risk evaluation of insuman implantable versus insuplant using medtronic minimed implantable pump system in patients with type 1 diabetes. ClinicalTrials.gov NCT01194882; 2010.
42. Food and Drug Administration. FDA approves Afrezza to treat diabetes. http://www.fda.gov/newsevents/newsroom/pressan-nouncements/ucm403122.htm. Accessed August 28, 2014.
43. Klonoff DC. Afrezza inhaled insulin: the fastest-acting FDA-approved insulin on the market has favorable properties. J Diabetes Sci Technol. 2014;8(6):1071-1073.
44. In Silico model and computer simulation approximating the human glucose/insulin utilization: Food and Drug Administration Master File MAF-1521 [computer program]. 2008.
45. Zisser CH, Dassau E, Bevier W, Harvey RA, Jovanovic L, Doyle FJ III. Clinical evaluation of a fully-automated artificial pancreas using zone-model predictive control with health monitoring system. In: 72nd American Diabetes Association Meeting. Vol. 61 (suppl. 1). Philadelphia, PA: Diabetes 2012:LB8.
46. Harvey RA, Dassau E, Bevier WC, et al. Clinical evaluation of an automated artificial pancreas using zone-model predictive control and health monitoring system. Diabetes Technol Ther. 2014;16(6):348-357.
47. Dassau E, Jimenez ND, Zisser H, Jovanovic L, Doyle FJ III. The artificial pancreas system: a comprehensive system for the clinical evaluation of control algorithms. Paper presented at: 4th International Conference on Advanced Technologies & Treatments for Diabetes, 2011; London, UK.
48. Grosman B, Dassau E, Zisser HC, Jovanovic L, Doyle FJ III. Zone model predictive control: a strategy to minimize hyper-and hypoglycemic events. J Diabetes Sci Technol. 2010;4(4):961-975.
49. Harvey RA, Dassau E, Zisser CH, Seborg DE, Jovanovic L, Doyle FJ III. Design of the health monitoring system for the artificial pancreas: low glucose prediction module. J Diabetes Sci Technol. 2012;6(2):1345-4354.
50. Karvonen MJ, Kentala E, Mustala O. The effects of training on heart rate; a longitudinal study. Ann Med Exp Biol Fenn. 1957;35(3):307-315.